International Flavors & Fragrances Inc. (IFF) Stock Analysis
Is IFF a good investment?
International Flavors & Fragrances Inc. (IFF) has a Plutrex AI rating of 28.0/100 as of November 13, 2026, indicating a Strong Sell consensus. The stock is not classified as halal-compliant. Key strength: FCF of $499M demonstrates real cash generation capacity that vastly exceeds net income (~$150M), driven by non-cash amortization masking true cash economics; FCF yield at $80.38 ≈ 3.1% (assuming ~258M shares, market cap ~$20.7B) provides partial valuation floor and supports dividend and debt service sustainability. Main concern: Catastrophic and worsening overvaluation: P/E expanded from 84.23x to 114.93x (+36.4%) and PEG expanded from 31.08x to 56.34x (+81.3%) as the stock fell 11.5% — earnings deteriorated FASTER than price, meaning the correction has not addressed the valuation problem; at industry-average P/E 31.90x applied to normalized EPS ~$0.75-1.00, fair value is approximately $24-32, implying 60-70% downside from $80.38; the analyst target of $102.67 is built on assumptions contradicted by 5-year EPS CAGR 2.04% versus industry 12.47%.
Investment Summary
IFF is a deeply troubled specialty chemicals/ingredients company trading at extreme valuation multiples that bear no relationship to its fundamental business quality. At $80.38 (down 11.5% from prior $90.81), the stock has partially corrected but remains severely overvalued: P/E of 114.93x (versus industry 31.90x, a 260% premium), PEG of 56.34x (versus industry 6.53x, a 763% premium), net margin of only 1.97% (versus industry 8.78%), and ROE of 0.67% (versus industry 13.14%). Despite the price decline, the multiple has actually expanded — P/E went from 84.23x to 114.93x because earnings deteriorated faster than price (-21.1% EPS YoY). The only genuine positives are FCF of $499M (real cash generation masking GAAP weakness), D/E of 0.39x (50.6% below industry average), and next-year EPS growth of 16.83% (66.8% above industry). News is modestly positive: IFF beat Q3 earnings and revenue estimates (headline: 'International Flavors (IFF) Surpasses Q3 Earnings and Revenue Estimates'), launched AI platform CONCEPT MUSE, and published a GLP-1 consumer insights report. However, management guided Q4 lower due to weak health market conditions and higher costs — a material negative. At fair value (industry P/E 31.90x × normalized earnings), IFF should trade near $25-35, implying 56-69% downside from current levels. Analyst consensus target of $102.67 offers 27.7% upside but is built on optimistic recovery assumptions that the 5-year EPS CAGR of only 2.04% flatly contradicts.
Key Strengths
- FCF of $499M demonstrates real cash generation capacity that vastly exceeds net income (~$150M), driven by non-cash amortization masking true cash economics; FCF yield at $80.38 ≈ 3.1% (assuming ~258M shares, market cap ~$20.7B) provides partial valuation floor and supports dividend and debt service sustainability
- D/E of 0.39x is 50.6% below industry average 0.79x — lowest leverage profile among specialty chemicals peers, providing balance sheet flexibility and meaningful protection against financial distress given the weak profitability environment; combined with $272M cash, near-term liquidity is acceptable
- Next-year EPS growth 16.83% beats industry 10.09% by 66.8% — the strongest relative metric in IFF's profile, and the Q3 earnings beat ('International Flavors (IFF) Surpasses Q3 Earnings and Revenue Estimates') plus CONCEPT MUSE AI platform launch signal active operational recovery and product innovation momentum
Key Concerns
- Catastrophic and worsening overvaluation: P/E expanded from 84.23x to 114.93x (+36.4%) and PEG expanded from 31.08x to 56.34x (+81.3%) as the stock fell 11.5% — earnings deteriorated FASTER than price, meaning the correction has not addressed the valuation problem; at industry-average P/E 31.90x applied to normalized EPS ~$0.75-1.00, fair value is approximately $24-32, implying 60-70% downside from $80.38; the analyst target of $102.67 is built on assumptions contradicted by 5-year EPS CAGR 2.04% versus industry 12.47%
- Structural profitability and growth crisis: ROE 0.67% is -94.9% below industry 13.14%; operating margin 8.13% is -50.1% below industry 16.28%; net margin 1.97% is -77.6% below industry 8.78%; revenue growth 3.9% is -73.6% below industry 14.79%; management guided Q4 lower citing weak health market conditions and higher costs — the near-term recovery narrative is undermined by both structural metrics and management's own forward guidance
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
IFF's fundamentals remain structurally impaired. Gross margin 34.1% (beats industry 31.73% by 7.5%) is the only profitability bright spot at the product level. Operating margin 8.13% collapses to -50.1% below industry average 16.28% — 26 percentage points of gross profit consumed by SG&A, R&D, and DuPont N&B acquisition amortization. Net margin 1.97% is -77.6% below industry 8.78%, retaining less than $0.02 per revenue dollar. ROE 0.67% is catastrophically -94.9% below industry 13.14% — generating 1/20th the shareholder return of average peers. EPS growth YoY -21.1% confirms ongoing earnings deterioration. Revenue growth improved to 3.9% from prior 1.8%, a genuine positive but still -73.6% below industry 14.79%. Forward EPS growth 16.83% next year beats industry 10.09% — the one meaningful near-term positive — but 5-year EPS CAGR 2.04% is -83.6% below industry 12.47%, exposing the recovery as cyclical, not structural. FCF $499M (down from prior $536M) remains the critical lifeline, supporting D/E 0.39x and thin cash of $272M. The business is cash-generative but earns nothing for equity holders. P/E 114.93x and PEG 56.34x represent catastrophic overvaluation versus any reasonable fundamental framework.
News Sentiment
International Flavors & Fragrances just delivered a mixed bag for investors — beating expectations in some areas while warning of tougher times ahead. The company surpassed Wall Street's Q3 earnings and revenue estimates (headline: 'International Flavors (IFF) Surpasses Q3 Earnings and Revenue Estimates'), which sounds great on the surface and sent a brief wave of optimism through the market. The Q3 earnings call highlighted both revenue and EPS as key performance indicators, and the results came in better than analysts feared. But here's the catch: management immediately tempered enthusiasm by cautioning that weak health market conditions and higher costs will squeeze Q4 profitability — a warning that investors can't ignore. On the innovation front, IFF has been busy. The company launched CONCEPT MUSE (headline: 'IFF Launches CONCEPT MUSE, an AI-Powered Platform Designed to Accelerate Food and...'), an artificial intelligence tool designed to help clients develop food products faster. If it works as advertised, it could drive more ingredient orders as concepts move from idea to store shelf. IFF also released a research report called 'GLP-1 Consumer Moments of Opportunity,' identifying ten emerging consumer behaviors among people taking GLP-1 weight-loss medications like Ozempic — a potentially large growth market for specialty ingredients. International revenue trends are also drawing analyst attention (headline: 'Why International Flavors (IFF) International Revenue Trends Deserve Your Attention'), suggesting global markets could be a growth driver. The story is one of a company fighting hard to recover, with real innovation efforts, but structural cost challenges and weak market conditions creating persistent headwinds.
Risk Assessment
PRIMARY RISK: Multiple compression. P/E of 114.93x on a 2% long-term growth business is the most dangerous valuation setup in this analysis. If the multiple compresses to even 50x (still generous), the stock trades at ~$35. At industry-average 31.90x, fair value is ~$25-32. The stock has already fallen 11.5% from $90.81 yet the P/E EXPANDED because EPS fell faster — this is the classic value trap pattern. SECONDARY RISK: Q4 guidance cut. Management explicitly cautioned that weak health market conditions and higher costs will pressure Q4 profitability, which risks triggering another EPS downward revision cycle that could push the already-elevated PE even higher. TERTIARY RISK: FCF sustainability. FCF fell from $536M (prior) to $499M — a $37M decline. If operating conditions deteriorate further in Q4 as guided, FCF could compress further, weakening the one genuine fundamental support. MITIGATION: Hold (not Sell) for existing shareholders because FCF $499M, D/E 0.39x, and analyst consensus target $102.67 (+27.7%) prevent immediate capitulation; a stop at $50 (-37.8% from current) is the absolute floor. NEW MONEY: Do not initiate above $62. Entry zone $56-$62 reduces downside to stop ($50) to 8-13%, while upside to analyst target ($102.67) = 65-83%, yielding acceptable risk/reward of ~5:1 — only achievable with deep margin of safety given the structural overvaluation.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is IFF a halal stock?
No, International Flavors & Fragrances Inc. (IFF) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for IFF?
International Flavors & Fragrances Inc. (IFF) has a Plutrex AI rating of 28.0/100 with a Strong Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is IFF a good investment?
According to Plutrex AI, IFF has a Strong Sell rating (28.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in IFF?
US stocks like IFF can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in IFF?
Plutrex AI identifies the main risks for IFF by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.